High cytomegalovirus serology and subsequent COPD-related mortality: a longitudinal study

Positive serology for cytomegalovirus (CMV) has been associated with all-cause mortality risk but its role in COPD mortality is unknown. The objective of the present study was to assess the relationship between CMV serology and COPD mortality. We analysed data from 806 participants in the Tucson Epi...

Full description

Saved in:
Bibliographic Details
Published in:ERJ open research 2020-04, Vol.6 (2), p.62
Main Authors: Nenna, Raffaella, Zhai, Jing, Packard, Samuel E, Spangenberg, Amber, Sherrill, Duane L, Martinez, Fernando D, Halonen, Marilyn, Guerra, Stefano
Format: Article
Language:English
Subjects:
Original
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c471t-55785a281d40f8af0cbb9882371ae9373c31214cb0e81f9bc9d17984211cddfe3
cites cdi_FETCH-LOGICAL-c471t-55785a281d40f8af0cbb9882371ae9373c31214cb0e81f9bc9d17984211cddfe3
container_end_page
container_issue 2
container_start_page 62
container_title ERJ open research
container_volume 6
creator Nenna, Raffaella
Zhai, Jing
Packard, Samuel E
Spangenberg, Amber
Sherrill, Duane L
Martinez, Fernando D
Halonen, Marilyn
Guerra, Stefano
description Positive serology for cytomegalovirus (CMV) has been associated with all-cause mortality risk but its role in COPD mortality is unknown. The objective of the present study was to assess the relationship between CMV serology and COPD mortality. We analysed data from 806 participants in the Tucson Epidemiological Study of Airway Obstructive Disease who, at enrolment, were aged 28-70 years and had completed lung function tests. We tested CMV serology in sera from enrolment and defined "high CMV serology" as being in the highest tertile. Vital status, date and cause of death were assessed through death certificates and/or linkage with the National Death Index up to January 2017. The association of CMV serology with all-cause and cause-specific mortality risk was tested in Cox models adjusted for age, sex, level of education, body mass index, smoking status and pack-years. High CMV serology was marginally associated with all-cause mortality (p=0.071) but the effect was inversely dependent on age, with the association being much stronger among participants
doi_str_mv 10.1183/23120541.00062-2020
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_300eef22809a4f85b81d1921569f43b4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_300eef22809a4f85b81d1921569f43b4</doaj_id><sourcerecordid>2398158831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-55785a281d40f8af0cbb9882371ae9373c31214cb0e81f9bc9d17984211cddfe3</originalsourceid><addsrcrecordid>eNpVkUtr3TAQhU1paUKaX1AoWnbjVKOHLXVRKLePBALpol10JWQ9HAXZSiU74H9f3dwkJCsNR2e-0eg0zXvAZwCCfiIUCOYMzjDGHWkJJvhVc7xX2738-ll91JyWclN9wIlgXfe2OaKEdpRgcdz8PQ_jNTLbkiY36pjuQl4LKi6nmMYN6dmisg7F_VvdvKDd1a9vbXZRL86iKeVFx7Bsn5FGMc1jWFYbZh1RqcX2rnnjdSzu9OE8af78-P57d95eXv282H29bA3rYWk57wXXRIBl2AvtsRkGKQShPWgnaU9N3QOYGbAT4OVgpIVeCkYAjLXe0ZPm4sC1Sd-o2xwmnTeVdFD3Qsqj0nkJJjpFMXbOEyKw1MwLPtSpIAnwTnpGB1ZZXw6s23WYnDV156zjC-jLmzlcqzHdqR4EA-AV8PEBkFP9srKoKRTjYtSzS2tRhEoBXAgK1UoPVpNTKdn5pzGA1T5j9Zixus9Y7TOuXR-ev_Cp5zFR-h8IxKIJ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2398158831</pqid></control><display><type>article</type><title>High cytomegalovirus serology and subsequent COPD-related mortality: a longitudinal study</title><source>Open Access: PubMed Central</source><creator>Nenna, Raffaella ; Zhai, Jing ; Packard, Samuel E ; Spangenberg, Amber ; Sherrill, Duane L ; Martinez, Fernando D ; Halonen, Marilyn ; Guerra, Stefano</creator><creatorcontrib>Nenna, Raffaella ; Zhai, Jing ; Packard, Samuel E ; Spangenberg, Amber ; Sherrill, Duane L ; Martinez, Fernando D ; Halonen, Marilyn ; Guerra, Stefano</creatorcontrib><description>Positive serology for cytomegalovirus (CMV) has been associated with all-cause mortality risk but its role in COPD mortality is unknown. The objective of the present study was to assess the relationship between CMV serology and COPD mortality. We analysed data from 806 participants in the Tucson Epidemiological Study of Airway Obstructive Disease who, at enrolment, were aged 28-70 years and had completed lung function tests. We tested CMV serology in sera from enrolment and defined "high CMV serology" as being in the highest tertile. Vital status, date and cause of death were assessed through death certificates and/or linkage with the National Death Index up to January 2017. The association of CMV serology with all-cause and cause-specific mortality risk was tested in Cox models adjusted for age, sex, level of education, body mass index, smoking status and pack-years. High CMV serology was marginally associated with all-cause mortality (p=0.071) but the effect was inversely dependent on age, with the association being much stronger among participants &lt;55 years than among participants ≥55 years at enrolment (p-value for CMV-by-age interaction &lt;0.001). Compared with low CMV serology, high CMV serology was associated with mortality from COPD among all subjects (adjusted hazard ratio (HR) 2.38, 95% CI 1.11-5.08; p=0.025) and particularly in subjects &lt;55 years old at enrolment (HR 5.40, 95% CI 1.73-16.9; p=0.004). Consistent with these results, high CMV serology also predicted mortality risk among subjects who already had airflow limitation at enrolment (HR 2.10, 95% CI 1.20-3.68; p=0.009). We report a strong relationship between CMV serology and the risk of dying from COPD, and thus identify a novel risk factor for COPD mortality.</description><identifier>ISSN: 2312-0541</identifier><identifier>EISSN: 2312-0541</identifier><identifier>DOI: 10.1183/23120541.00062-2020</identifier><identifier>PMID: 32363208</identifier><language>eng</language><publisher>England: European Respiratory Society</publisher><subject>Original</subject><ispartof>ERJ open research, 2020-04, Vol.6 (2), p.62</ispartof><rights>Copyright ©ERS 2020.</rights><rights>Copyright ©ERS 2020 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-55785a281d40f8af0cbb9882371ae9373c31214cb0e81f9bc9d17984211cddfe3</citedby><cites>FETCH-LOGICAL-c471t-55785a281d40f8af0cbb9882371ae9373c31214cb0e81f9bc9d17984211cddfe3</cites><orcidid>0000-0001-8880-3462</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184115/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184115/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32363208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nenna, Raffaella</creatorcontrib><creatorcontrib>Zhai, Jing</creatorcontrib><creatorcontrib>Packard, Samuel E</creatorcontrib><creatorcontrib>Spangenberg, Amber</creatorcontrib><creatorcontrib>Sherrill, Duane L</creatorcontrib><creatorcontrib>Martinez, Fernando D</creatorcontrib><creatorcontrib>Halonen, Marilyn</creatorcontrib><creatorcontrib>Guerra, Stefano</creatorcontrib><title>High cytomegalovirus serology and subsequent COPD-related mortality: a longitudinal study</title><title>ERJ open research</title><addtitle>ERJ Open Res</addtitle><description>Positive serology for cytomegalovirus (CMV) has been associated with all-cause mortality risk but its role in COPD mortality is unknown. The objective of the present study was to assess the relationship between CMV serology and COPD mortality. We analysed data from 806 participants in the Tucson Epidemiological Study of Airway Obstructive Disease who, at enrolment, were aged 28-70 years and had completed lung function tests. We tested CMV serology in sera from enrolment and defined "high CMV serology" as being in the highest tertile. Vital status, date and cause of death were assessed through death certificates and/or linkage with the National Death Index up to January 2017. The association of CMV serology with all-cause and cause-specific mortality risk was tested in Cox models adjusted for age, sex, level of education, body mass index, smoking status and pack-years. High CMV serology was marginally associated with all-cause mortality (p=0.071) but the effect was inversely dependent on age, with the association being much stronger among participants &lt;55 years than among participants ≥55 years at enrolment (p-value for CMV-by-age interaction &lt;0.001). Compared with low CMV serology, high CMV serology was associated with mortality from COPD among all subjects (adjusted hazard ratio (HR) 2.38, 95% CI 1.11-5.08; p=0.025) and particularly in subjects &lt;55 years old at enrolment (HR 5.40, 95% CI 1.73-16.9; p=0.004). Consistent with these results, high CMV serology also predicted mortality risk among subjects who already had airflow limitation at enrolment (HR 2.10, 95% CI 1.20-3.68; p=0.009). We report a strong relationship between CMV serology and the risk of dying from COPD, and thus identify a novel risk factor for COPD mortality.</description><subject>Original</subject><issn>2312-0541</issn><issn>2312-0541</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUtr3TAQhU1paUKaX1AoWnbjVKOHLXVRKLePBALpol10JWQ9HAXZSiU74H9f3dwkJCsNR2e-0eg0zXvAZwCCfiIUCOYMzjDGHWkJJvhVc7xX2738-ll91JyWclN9wIlgXfe2OaKEdpRgcdz8PQ_jNTLbkiY36pjuQl4LKi6nmMYN6dmisg7F_VvdvKDd1a9vbXZRL86iKeVFx7Bsn5FGMc1jWFYbZh1RqcX2rnnjdSzu9OE8af78-P57d95eXv282H29bA3rYWk57wXXRIBl2AvtsRkGKQShPWgnaU9N3QOYGbAT4OVgpIVeCkYAjLXe0ZPm4sC1Sd-o2xwmnTeVdFD3Qsqj0nkJJjpFMXbOEyKw1MwLPtSpIAnwTnpGB1ZZXw6s23WYnDV156zjC-jLmzlcqzHdqR4EA-AV8PEBkFP9srKoKRTjYtSzS2tRhEoBXAgK1UoPVpNTKdn5pzGA1T5j9Zixus9Y7TOuXR-ev_Cp5zFR-h8IxKIJ</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Nenna, Raffaella</creator><creator>Zhai, Jing</creator><creator>Packard, Samuel E</creator><creator>Spangenberg, Amber</creator><creator>Sherrill, Duane L</creator><creator>Martinez, Fernando D</creator><creator>Halonen, Marilyn</creator><creator>Guerra, Stefano</creator><general>European Respiratory Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8880-3462</orcidid></search><sort><creationdate>20200401</creationdate><title>High cytomegalovirus serology and subsequent COPD-related mortality: a longitudinal study</title><author>Nenna, Raffaella ; Zhai, Jing ; Packard, Samuel E ; Spangenberg, Amber ; Sherrill, Duane L ; Martinez, Fernando D ; Halonen, Marilyn ; Guerra, Stefano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-55785a281d40f8af0cbb9882371ae9373c31214cb0e81f9bc9d17984211cddfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nenna, Raffaella</creatorcontrib><creatorcontrib>Zhai, Jing</creatorcontrib><creatorcontrib>Packard, Samuel E</creatorcontrib><creatorcontrib>Spangenberg, Amber</creatorcontrib><creatorcontrib>Sherrill, Duane L</creatorcontrib><creatorcontrib>Martinez, Fernando D</creatorcontrib><creatorcontrib>Halonen, Marilyn</creatorcontrib><creatorcontrib>Guerra, Stefano</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>ERJ open research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nenna, Raffaella</au><au>Zhai, Jing</au><au>Packard, Samuel E</au><au>Spangenberg, Amber</au><au>Sherrill, Duane L</au><au>Martinez, Fernando D</au><au>Halonen, Marilyn</au><au>Guerra, Stefano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High cytomegalovirus serology and subsequent COPD-related mortality: a longitudinal study</atitle><jtitle>ERJ open research</jtitle><addtitle>ERJ Open Res</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>6</volume><issue>2</issue><spage>62</spage><pages>62-</pages><issn>2312-0541</issn><eissn>2312-0541</eissn><abstract>Positive serology for cytomegalovirus (CMV) has been associated with all-cause mortality risk but its role in COPD mortality is unknown. The objective of the present study was to assess the relationship between CMV serology and COPD mortality. We analysed data from 806 participants in the Tucson Epidemiological Study of Airway Obstructive Disease who, at enrolment, were aged 28-70 years and had completed lung function tests. We tested CMV serology in sera from enrolment and defined "high CMV serology" as being in the highest tertile. Vital status, date and cause of death were assessed through death certificates and/or linkage with the National Death Index up to January 2017. The association of CMV serology with all-cause and cause-specific mortality risk was tested in Cox models adjusted for age, sex, level of education, body mass index, smoking status and pack-years. High CMV serology was marginally associated with all-cause mortality (p=0.071) but the effect was inversely dependent on age, with the association being much stronger among participants &lt;55 years than among participants ≥55 years at enrolment (p-value for CMV-by-age interaction &lt;0.001). Compared with low CMV serology, high CMV serology was associated with mortality from COPD among all subjects (adjusted hazard ratio (HR) 2.38, 95% CI 1.11-5.08; p=0.025) and particularly in subjects &lt;55 years old at enrolment (HR 5.40, 95% CI 1.73-16.9; p=0.004). Consistent with these results, high CMV serology also predicted mortality risk among subjects who already had airflow limitation at enrolment (HR 2.10, 95% CI 1.20-3.68; p=0.009). We report a strong relationship between CMV serology and the risk of dying from COPD, and thus identify a novel risk factor for COPD mortality.</abstract><cop>England</cop><pub>European Respiratory Society</pub><pmid>32363208</pmid><doi>10.1183/23120541.00062-2020</doi><orcidid>https://orcid.org/0000-0001-8880-3462</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2312-0541
ispartof ERJ open research, 2020-04, Vol.6 (2), p.62
issn 2312-0541
2312-0541
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_300eef22809a4f85b81d1921569f43b4
source Open Access: PubMed Central
subjects Original
title High cytomegalovirus serology and subsequent COPD-related mortality: a longitudinal study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T05%3A53%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20cytomegalovirus%20serology%20and%20subsequent%20COPD-related%20mortality:%20a%20longitudinal%20study&rft.jtitle=ERJ%20open%20research&rft.au=Nenna,%20Raffaella&rft.date=2020-04-01&rft.volume=6&rft.issue=2&rft.spage=62&rft.pages=62-&rft.issn=2312-0541&rft.eissn=2312-0541&rft_id=info:doi/10.1183/23120541.00062-2020&rft_dat=%3Cproquest_doaj_%3E2398158831%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c471t-55785a281d40f8af0cbb9882371ae9373c31214cb0e81f9bc9d17984211cddfe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2398158831&rft_id=info:pmid/32363208&rfr_iscdi=true